CSIMarket Company Name, Ticker, Customers, else..
 
Bolt Biotherapeutics Inc   (NASDAQ: BOLT)
Other Ticker:  
 
 
Price: $0.5150 $-0.01 -2.683%
Day's High: $0.53 Week Perf: -11.57 %
Day's Low: $ 0.51 30 Day Perf: -9.65 %
Volume (M): 148 52 Wk High: $ 1.56
Volume (M$): $ 76 52 Wk Avg: $0.84
Open: $0.53 52 Wk Low: $0.47



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 38
 Employees 30
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Bolt Biotherapeutics Inc
Bolt Biotherapeutics Inc is a biotechnology company focused on developing immune-stimulating therapies for cancer treatment. The company's proprietary Immune-Stimulating Antibody Conjugates (ISACs) aim to enhance the body's immune response to specifically target and kill cancer cells. Bolt Biotherapeutics' therapies utilize a unique approach that combines the specificity of monoclonal antibodies with the ability to activate the immune system. By leveraging this technology, the company aims to provide more effective and durable treatments for patients with various types of cancer.


   Company Address: 900 Chesapeake Redwood City 94063 CA
   Company Phone Number: 665-9295   Stock Exchange / Ticker: NASDAQ BOLT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -1.88%    
JNJ        1.74% 
LLY   -5.37%    
MRK   -0.2%    
TEVA   -2.37%    
VTRS   -2.01%    
• View Complete Report
   



Clinical Study

Advancements in Cancer Immunotherapy Insights from Bolt Biotherapeutics BDC-4182 and BDC-1001

Published Thu, Nov 7 2024 3:00 PM UTC

Abstract: Recent advancements in the realm of immunotherapy have showcased significant potential in battling cancer due to innovative approaches that harness the immune system. This article delves into the promising preclinical data for BDC-4182 presented by Bolt Biotherapeutics, alongside crucial findings from the Phase 1 dose-escalation trial of BDC-1001 at the 39th Annu...
Announcement

Navigating Legal Turbulence The Impact of Securities Class Action on Bolt Biotherapeutics,

Published Wed, Aug 14 2024 6:23 PM UTC

Navigating Legal Waters: The Bolt Biotherapeutics Securities Class Action and Its Implications In recent news, Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage immuno-oncology company, has found itself at the center of a securities class action lawsuit. The Rosen Law Firm, known for its expertise in investor rights, has actively encouraged investors who purchased ...
Announcement

Bolt Biotherapeutics Faces Investor Investigation by Pomerantz Law Firm: Is Trouble Brewing for the Company

Published Wed, Jun 5 2024 7:26 PM UTC

Sophisticated New York-based law firm, Pomerantz LLP, has initiated an investigation into the claims made by investors of Bolt Biotherapeutics, Inc. (Bolt or the Company) (NASDAQ: BOLT). With rising concerns over potential misconduct or violations of regulatory obligations, shareholders are urged to contact Danielle Peyton, at newaction@pomlaw.com or 646-581-9980, ext. 7980,...
Clinical Study

Bolt Biotherapeutics Enters Phase 2 Trial with BDC-1001, Potentially Revolutionizing HER2-Positive Breast Cancer Treatment, Amidst Revenue Growth

Published Tue, Dec 5 2023 12:00 PM UTC


Bolt Biotherapeutics Initiates Phase 2 Study for BDC-1001 in HER2-Positive Breast Cancer Patients Previously Treated with Enhertu
REDWOOD CITY, Calif., Dec. 05, 2023 - Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a leading biopharmaceutical company specializing in novel immunotherapies for cancer treatment, has announced the enrollment of the first patient in their Ph...
Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc Demonstrates Robust Growth and Sustained Progress Throughout Q3 2023

In the third quarter of 2023, Bolt Biotherapeutics Inc, a major player in the Major Pharmaceutical Preparations industry, showed signs of improvement despite a challenging environment for the industry as a whole. The company reported a decreased loss per share of $-0.43, compared to $-0.58 in the same quarter the previous year. Additionally, income per share improved from $-0.48 in the previous quarter.
One of the key highlights for Bolt Biotherapeutics Inc in the third quarter was a considerable increase in revenue. The company's revenue rose by 19.697% to $2.53 million from $2.11 million in the same quarter a year earlier. Sequentially, the revenue surged by an impressive 76.413% from $1.43 million in the previous quarter.






Bolt Biotherapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com